412 related articles for article (PubMed ID: 12631109)
1. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.
Gross O; Beirowski B; Koepke ML; Kuck J; Reiner M; Addicks K; Smyth N; Schulze-Lohoff E; Weber M
Kidney Int; 2003 Feb; 63(2):438-46. PubMed ID: 12631109
[TBL] [Abstract][Full Text] [Related]
2. Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome.
Koepke ML; Weber M; Schulze-Lohoff E; Beirowski B; Segerer S; Gross O
Nephrol Dial Transplant; 2007 Apr; 22(4):1062-9. PubMed ID: 17287218
[TBL] [Abstract][Full Text] [Related]
3. Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis.
Gross O; Schulze-Lohoff E; Koepke ML; Beirowski B; Addicks K; Bloch W; Smyth N; Weber M
Nephrol Dial Transplant; 2004 Jul; 19(7):1716-23. PubMed ID: 15128880
[TBL] [Abstract][Full Text] [Related]
4. Chronic renal failure and shortened lifespan in COL4A3+/- mice: an animal model for thin basement membrane nephropathy.
Beirowski B; Weber M; Gross O
J Am Soc Nephrol; 2006 Jul; 17(7):1986-94. PubMed ID: 16775036
[TBL] [Abstract][Full Text] [Related]
5. Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688.
Gross O; Koepke ML; Beirowski B; Schulze-Lohoff E; Segerer S; Weber M
Kidney Int; 2005 Aug; 68(2):456-63. PubMed ID: 16014022
[TBL] [Abstract][Full Text] [Related]
6. Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis.
Rubel D; Stock J; Ciner A; Hiller H; Girgert R; Müller GA; Gross O
Nephrol Dial Transplant; 2014 May; 29(5):1012-9. PubMed ID: 24198271
[TBL] [Abstract][Full Text] [Related]
7. Collagen receptors integrin alpha2beta1 and discoidin domain receptor 1 regulate maturation of the glomerular basement membrane and loss of integrin alpha2beta1 delays kidney fibrosis in COL4A3 knockout mice.
Rubel D; Frese J; Martin M; Leibnitz A; Girgert R; Miosge N; Eckes B; Müller GA; Gross O
Matrix Biol; 2014 Feb; 34():13-21. PubMed ID: 24480069
[TBL] [Abstract][Full Text] [Related]
8. Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome.
Bae EH; Fang F; Williams VR; Konvalinka A; Zhou X; Patel VB; Song X; John R; Oudit GY; Pei Y; Scholey JW
Kidney Int; 2017 Jun; 91(6):1347-1361. PubMed ID: 28249676
[TBL] [Abstract][Full Text] [Related]
9. A Neutralizing IL-11 Antibody Improves Renal Function and Increases Lifespan in a Mouse Model of Alport Syndrome.
Widjaja AA; Shekeran SG; Adami E; Ting JGW; Tan J; Viswanathan S; Lim SY; Tan PH; Hübner N; Coffman T; Cook SA
J Am Soc Nephrol; 2022 Apr; 33(4):718-730. PubMed ID: 35140116
[TBL] [Abstract][Full Text] [Related]
10. Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease.
Gross O; Girgert R; Beirowski B; Kretzler M; Kang HG; Kruegel J; Miosge N; Busse AC; Segerer S; Vogel WF; Müller GA; Weber M
Matrix Biol; 2010 Jun; 29(5):346-56. PubMed ID: 20307660
[TBL] [Abstract][Full Text] [Related]
11. Endothelial cell-specific collagen type IV-α
Funk SD; Bayer RH; Miner JH
Am J Physiol Renal Physiol; 2019 May; 316(5):F830-F837. PubMed ID: 30724107
[TBL] [Abstract][Full Text] [Related]
12. Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease.
Zeisberg M; Khurana M; Rao VH; Cosgrove D; Rougier JP; Werner MC; Shield CF; Werb Z; Kalluri R
PLoS Med; 2006 Apr; 3(4):e100. PubMed ID: 16509766
[TBL] [Abstract][Full Text] [Related]
13. Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy.
Cosgrove D; Rodgers K; Meehan D; Miller C; Bovard K; Gilroy A; Gardner H; Kotelianski V; Gotwals P; Amatucci A; Kalluri R
Am J Pathol; 2000 Nov; 157(5):1649-59. PubMed ID: 11073824
[TBL] [Abstract][Full Text] [Related]
14. CG200745, a Novel HDAC Inhibitor, Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome.
Suh SH; Choi HS; Kim CS; Kim IJ; Cha H; Cho JM; Ma SK; Kim SW; Bae EH
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098220
[TBL] [Abstract][Full Text] [Related]
15. Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis.
Mitrofanova A; Molina J; Varona Santos J; Guzman J; Morales XA; Ducasa GM; Bryn J; Sloan A; Volosenco I; Kim JJ; Ge M; Mallela SK; Kretzler M; Eddy S; Martini S; Wahl P; Pastori S; Mendez AJ; Burke GW; Merscher S; Fornoni A
Kidney Int; 2018 Dec; 94(6):1151-1159. PubMed ID: 30301568
[TBL] [Abstract][Full Text] [Related]
16. Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis.
Gross O; Girgert R; Rubel D; Temme J; Theissen S; Müller GA
Am J Hypertens; 2011 Mar; 24(3):355-61. PubMed ID: 21127470
[TBL] [Abstract][Full Text] [Related]
17. Progression of Alport Kidney Disease in Col4a3 Knock Out Mice Is Independent of Sex or Macrophage Depletion by Clodronate Treatment.
Kim M; Piaia A; Shenoy N; Kagan D; Gapp B; Kueng B; Weber D; Dietrich W; Ksiazek I
PLoS One; 2015; 10(11):e0141231. PubMed ID: 26555339
[TBL] [Abstract][Full Text] [Related]
18. Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.
Zhu Z; Rosenkranz KAT; Kusunoki Y; Li C; Klaus M; Gross O; Angelotti ML; Antonelli G; Cirillo L; Romagnani P; Bouteldja N; Sadr AV; Bülow RD; Boor P; Anders HJ
J Am Soc Nephrol; 2023 Sep; 34(9):1513-1520. PubMed ID: 37428955
[TBL] [Abstract][Full Text] [Related]
19. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse.
Hahm K; Lukashev ME; Luo Y; Yang WJ; Dolinski BM; Weinreb PH; Simon KJ; Chun Wang L; Leone DR; Lobb RR; McCrann DJ; Allaire NE; Horan GS; Fogo A; Kalluri R; Shield CF; Sheppard D; Gardner HA; Violette SM
Am J Pathol; 2007 Jan; 170(1):110-25. PubMed ID: 17200187
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Alterations in the Serum of COL(IV)A3(-)/(-) Mice as Early Biomarkers of Alport Syndrome.
Muckova P; Wendler S; Rubel D; Büchler R; Alert M; Gross O; Rhode H
J Proteome Res; 2015 Dec; 14(12):5202-14. PubMed ID: 26487288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
